Frontier Epiproteomic Innovation Grant

At Promise Bio, we believe that breakthrough technology should be accessible to every innovator working to help patients. The most promising therapeutic advances often come from biotech companies with bold ideas but limited access to cutting-edge epiproteomic capabilities.

The Frontier Grant exists to bridge that gap. By providing comprehensive epiproteomic analysis at no cost, we aim to:

• Accelerate drug development timelines by enabling deeper molecular insights earlier in the process
• Democratize access to frontier technology that was previously available only to the largest organizations
• Empower innovators to pursue ambitious research questions that could transform patient outcomes
• Foster a community of scientists pushing the boundaries of translational medicine

Every day patients wait for therapies that could improve or save their lives. We're committed to giving biotech innovators the tools they need to move faster — because when science advances, patients benefit.

The Frontier Epiproteomic Innovation Grant is an R&D access initiative designed to support biotech companies advancing novel therapeutics with clear translational potential. Through this grant, Promise Bio provides selected recipients with comprehensive epiproteomic analysis for up to 200 samples, including:

• Quality control services
• Broad epiproteomic profiling via advanced mass spectrometry
• Detection and mapping of 64 post-translational modifications (PTMs)
• Expert analysis of PTMs and proteoforms specific to your data
• Advanced bioinformatics and scientific interpretation

Applicants must meet the following criteria:

• Company Type: Biotech companies at the clinical development stage
• Therapeutic Area: Focus on immunology, neurology, or cardio-renal-metabolic diseases
• Research Question: Must have a clearly defined, decision-relevant question that epiproteomic analysis can address
• Institutional Affiliation: Company must be a legally registered entity with appropriate research capabilities

Suitable question types include:

• Mechanism of action (MoA) elucidation: How does our therapeutic modulate target pathways?
• Biomarker discovery: What epiproteomic signatures predict drug response?
• Patient stratification: Can we identify molecular subtypes that respond differently?
• Drug-response prediction: How do post-translational modifications change with treatment?
• Disease mechanism: What epiproteomic changes distinguish disease from healthy states?

Not suitable: Purely descriptive studies without clear translational application, or questions that don't require epiproteomic depth.

Proposals are evaluated on four equally weighted criteria (25% each):

1. Scientific Merit & Team Expertise: Demonstrated expertise, track record, and quality of preliminary data
2. Impact & Translational Potential: Clarity of research question, potential to advance therapeutic development, and publication potential
3. Technology Alignment: Clear articulation of why epiproteomic analysis is necessary and how PromiseOS addresses the research gap
4. Experimental Design & Feasibility: Rigor of study design, feasibility of work plan, and appropriateness of samples

Our epiproteomic analysis supports multiple sample types:

• Plasma and serum
• Tissue samples (fresh frozen or FFPE)
• Cell culture samples (primary cells, cell lines)
• Other biological fluids (CSF, urine, synovial fluid — subject to feasibility review)

Grant recipients agree to:

• If invited, participate and present findings at a Frontier-sponsored session
• Acknowledge Frontier support in publications/presentations
• Share anonymized summary findings (proprietary details protected)
• Provide feedback to help improve the analysis platform
• Sign Service Agreement and Data Use Terms
• Ensure IRB/ethics approvals are in place

Important: Recipients retain full ownership of samples and data. Promise Bio does not claim IP rights to your discoveries.

Required materials:

1. Application Form: Company and PI information
2. Research Proposal: 5 pages max (Background, Aims, Design, Outcomes, References)
3. PI CV: NIH biosketch format, 5 pages max
4. Letter of Support: From company leadership
5. Preliminary Data: Optional, 2 pages max

Format: 11-point font minimum, 0.5-inch margins, PDF format